BioSig Appoints Andrew Ballou as Vice President of Investor Relations
October 29 2019 - 7:52AM
BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or “The
Company”), a medical technology company developing a proprietary
biomedical signal processing platform designed to improve signal
fidelity and uncover the full range of ECG and intra-cardiac
signals, today announced that the Company appointed Mr. Andrew
(“Andy”) Gornell Ballou as Vice President of Investor Relations.
Mr. Ballou brings to BioSig over 25 years of experience in
capital markets, including institutional equity sales and research
analysis. Most recently, Mr. Ballou served as Managing Director,
Head of Institutional Equity Sales at Janney Montgomery Scott LLC.,
a role in which he oversaw key accounts, including large
multi-manager hedge funds, mutual funds and dedicated sector funds.
Prior to that role Mr. Ballou managed selected key account coverage
at RBC Capital Markets, including Millennium Partners, Soros Fund
Management, SIR Capital, Columbia Threadneedle, Two Sigma
Investments and Times Square Capital Management. During the course
of his career Mr. Ballou analyzed various private and public
companies in healthcare, media and retail sectors. Mr. Ballou
graduated from Hampden-Sydney College, Virginia, with a Bachelor of
Arts in English.
“We pride ourselves on being a shareholder-friendly company, and
implementation of effective strategies to create long-term
shareholder value is one of our biggest priorities,” commented
Kenneth L. Londoner, Chairman and CEO of BioSig Technologies, Inc.
“Our Company’s management and the Board of Directors possess a
substantial collective skillset in capital markets, and we believe
Andy’s impressive Wall Street experience makes him the perfect fit
to head up our internal investor relations division, as we move
into our second year as a Nasdaq-listed company.”
“I have been impressed by the dedication of the Company’s
management to create long-term shareholder value through
appropriate allocation of Company’s human and financial resources.
That combined with a novel technology, a significant unmet clinical
need and first-class clinical partners, I believe, lead to a highly
exciting opportunity for institutional shareholders. I look forward
to contributing my skills and knowledge and raising awareness of
BioSig within fundamentals-driven institutional community,” said
Mr. Ballou.
BioSig stock was listed on the Nasdaq Capital Market exchange in
September 2018 and was recently added to the Russell 3000 Index.
About BioSig Technologies BioSig Technologies is a
medical technology company developing a proprietary biomedical
signal processing platform designed to improve the
electrophysiology (EP) marketplace (www.biosig.com). Led by a
proven management team and a veteran Board of Directors, BioSig
Technologies is preparing to commercialize its PURE EP(tm) System.
The technology has been developed to address an unmet need in a
large and growing market.
The Company’s first product, PURE EP(tm) System is a
computerized system intended for acquiring, digitizing, amplifying,
filtering, measuring and calculating, displaying, recording and
storing of electrocardiographic and intracardiac signals for
patients undergoing electrophysiology (EP) procedures in an EP
laboratory. The system is indicated for use under the supervision
of licensed healthcare practitioners who are responsible for
interpreting the data. This novel cardiac signal acquisition and
display system is engineered to assist electrophysiologists in
clinical decision-making during electrophysiology procedures in
patients with abnormal heart rates and rhythms. BioSig’s ultimate
goal is to deliver technology to improve upon catheter ablation
treatments for the prevalent and potentially deadly arrhythmias,
Atrial Fibrillation and Ventricular Tachycardia. BioSig has
partnered with Minnetronix on technology development and received
FDA 510(k) clearance for the PURE EP(tm) System in August 2018.
Forward-looking Statements This press release
contains “forward-looking statements.” Such statements may be
preceded by the words “intends,” “may,” “will,” “plans,” “expects,”
“anticipates,” “projects,” “predicts,” “estimates,” “aims,”
“believes,” “hopes,” “potential” or similar words. Forward- looking
statements are not guarantees of future performance, are based on
certain assumptions and are subject to various known and unknown
risks and uncertainties, many of which are beyond the Company’s
control, and cannot be predicted or quantified and consequently,
actual results may differ materially from those expressed or
implied by such forward-looking statements. Such risks and
uncertainties include, without limitation, risks and uncertainties
associated with (i) our inability to manufacture our products and
product candidates on a commercial scale on our own, or in
collaboration with third parties; (ii) difficulties in obtaining
financing on commercially reasonable terms; (iii) changes in the
size and nature of our competition; (iv) loss of one or more key
executives or scientists; and (v) difficulties in securing
regulatory approval to market our products and product candidates.
More detailed information about the Company and the risk factors
that may affect the realization of forward-looking statements is
set forth in the Company’s filings with the Securities and Exchange
Commission (SEC), including the Company’s Annual Report on Form
10-K and its Quarterly Reports on Form 10-Q. Investors and security
holders are urged to read these documents free of charge on the
SEC’s website at http://www.sec.gov. The Company assumes no
obligation to publicly update or revise its forward-looking
statements as a result of new information, future events or
otherwise.
Contact:
Natasha Drapeau
BioSig Technologies, Inc.
Executive Vice President
54 Wilton Road, 2nd floor
Westport, CT 06880
ndrapeau@biosigtech.com
203-409-5444, x119
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Mar 2024 to Apr 2024
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Apr 2023 to Apr 2024